Herpes Zoster Related Glaucoma

  • Edney R. Moura Filho
  • Thomas J. Liesegang


Varicella-zoster virus causes two distinct syndromes. Primary infection presents as varicella (or chickenpox), a contagious and usually benign childhood illness that occurs in epidemics among susceptible children. The reactivation of the virus, usually associated with decline in cell-mediated immunity, occurs as herpes zoster (HZ) (shingles). Varicella is spread through droplet infection with an initial viremia, and subsequent viral spread to the skin and the eye. It is easily disseminated to susceptible individuals. Ninety-five percent of the population has serological evidence of prior VZV infection with or without symptomatic varicella. The incidence of varicella has diminished 70% after implementation of the varicella vaccine in 1995.


Herpes Zoster Trabecular Meshwork Cystoid Macular Edema Anterior Uveitis Post Herpetic Neuralgia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Edgerton A. Herpes zoster ophthalmicus: report of cases and a review of the literature. Trans Am Ophthalmol Soc. 1942;40:390–439.PubMedGoogle Scholar
  2. 2.
    Harding SP. Management of ophthalmic zoster. J Med Virol. 1993;(Suppl 1):97–101.CrossRefPubMedGoogle Scholar
  3. 3.
    Harding SP, Lipton JR, Wells JC. Natural history of herpes zoster ophthalmicus: predictors of postherpetic neuralgia and ocular involvement. Br J Ophthalmol. 1987;71:353–358.CrossRefPubMedGoogle Scholar
  4. 4.
    Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115:S3-S12.CrossRefPubMedGoogle Scholar
  5. 5.
    Hutchinson J. A clinical report on herpes zoster ophthalmicus (shingles affecting the forehead and nose). R Lond Ophthalmic Hosp Rep. 1865;5:191–215.Google Scholar
  6. 6.
    Zaal MJ, Volker-Dieben HJ, D’Amaro J. Prognostic value of Hutchinson’s sign in acute herpes zoster ophthalmicus. Graefes Arch Clin Exp Ophthalmol. 2003;241:187–191.CrossRefPubMedGoogle Scholar
  7. 7.
    Thean JH, Hall AJ, Stawell RJ. Uveitis in Herpes zoster ophthalmicus. Clin Experiment Ophthalmol. 2001;29:406–410.CrossRefPubMedGoogle Scholar
  8. 8.
    Van der Lelij A, Ooijman FM, Kijlstra A, Rothova A. Anterior uveitis with sectoral iris atrophy in the absence of keratitis: a distinct clinical entity among herpetic eye diseases. Ophthalmology. 2000;107:1164–1170.CrossRefPubMedGoogle Scholar
  9. 9.
    Da Mata A, Burk SE, Netland PA, et al. Management of uveitic glaucoma with Ahmed glaucoma valve implantation. Ophthalmology. 1999;106:2168–2172.CrossRefPubMedGoogle Scholar
  10. 10.
    Molteno AC, Sayawat N, Herbison P. Otago glaucoma surgery outcome study: long-term results of uveitis with secondary glaucoma drained by Molteno implants. Ophthalmology. 2001;108:605–613.CrossRefPubMedGoogle Scholar
  11. 11.
    Ceballos EM, Parrish RK 2nd, Schiffman JC. Outcome of Baerveldt glaucoma drainage implants for the treatment of uveitic glaucoma. Ophthalmology. 2002;109:2256–2260.CrossRefPubMedGoogle Scholar
  12. 12.
    Kok H, Barton K. Uveitic glaucoma. Ophthalmol Clin North Am. 2002;15:375–387.CrossRefPubMedGoogle Scholar
  13. 13.
    Stjernschantz JW. From PGF(2alpha)-isopropyl ester to latanoprost: a review of the development of xalatan: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42:1134–1145.PubMedGoogle Scholar
  14. 14.
    Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol. 2002;133:393–397.CrossRefPubMedGoogle Scholar
  15. 15.
    Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular edema: is there a causal relation? Curr Opin Ophthalmol. 2000;11:94–100.CrossRefPubMedGoogle Scholar
  16. 16.
    Hoyng PF, Rulo AH, Greve EL, et al. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol. 1997;41(Suppl 2):S83-S88.CrossRefPubMedGoogle Scholar
  17. 17.
    Furuichi M, Chiba T, Abe K, et al. Cystoid macular edema associated with topical latanoprost in glaucomatous eyes with a normally functioning blood-ocular barrier. J Glaucoma. 2001;10:233–236.CrossRefPubMedGoogle Scholar
  18. 18.
    Chang JH, McCluskey P, Missotten T, Ferrante P, Jalaludin B, Lightman S. Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? Br J Ophthalmol. 2008;92:916–921.CrossRefPubMedGoogle Scholar
  19. 19.
    Neri P, Azuara-Blanco A, Forrester JV. Incidence of glaucoma in patients with uveitis. J Glaucoma. 2004;13:461–465.CrossRefPubMedGoogle Scholar
  20. 20.
    Pavan-Langston D, Yamamoto S, Dunkel EC. Delayed herpes zoster pseudodendrites. Polymerase chain reaction detection of viral DNA and a role for antiviral therapy. Arch Ophthalmol. 1995;113:1381–1385.PubMedGoogle Scholar
  21. 21.
    Marsh RJ, Cooper M. Ophthalmic zoster: mucous plaque keratitis. Br J Ophthalmol. 1987;71:725–728.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Edney R. Moura Filho
    • 1
  • Thomas J. Liesegang
    • 2
  1. 1.Mayo ClinicJacksonvilleUSA
  2. 2.Department of OphthalmologyMayo ClinicJacksonvilleUSA

Personalised recommendations